DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactOrders & Deals

Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targets

Economic Times 2d ago·28 Aug 2026, 7:58 am

Elara Securities has started fresh coverage on four major pharmaceutical companies, including IPCA Laboratories. The firm assigned different ratings to each stock based on their individual growth prospects and financial health. While some were rated as top picks, IPCA was given a cautious outlook.

For IPCA specifically, the rating reflects a wait-and-see approach following its recent rally. Investors are advised to monitor the company's ability to sustain its momentum and manage its costs effectively in the coming quarters.

Moving forward, investors should focus on IPCA's quarterly earnings reports and any updates regarding its product pipeline. Keeping an eye on broader market trends and competitive dynamics will also be crucial for making informed decisions.

Affected stocks

Bullish4 stocks

Alkem Laboratories

₹1,959.80

ERIS

—

IPCALAB

—

MANKIND

—

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Alkem Laboratories (ALKEM).
Category: Orders & Deals.
AI reads the tone as positive (potentially bullish) for the stock.
Assessed as a significant, market-relevant update.
Also mentions ERIS, IPCALAB, MANKIND.

Why it matters

A meaningful update for Alkem Laboratories worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Economic Times.